Cyclaid,25 mg, soft capsules
Cyclaid,50 mg, soft capsules
Cyclaid,100 mg, soft capsules
Cyclosporin
This medicine is called Cyclaid. It contains the active substance cyclosporin. This medicine belongs to a group of medicines called immunosuppressants. These medicines are used to reduce the body's immune response.
In patients taking Cyclaid after transplantation, this medicine will be prescribed only by a doctor with experience in transplantation and/or autoimmune diseases. The recommendations in this leaflet may vary depending on whether the patient is taking this medicine due to organ transplantation or autoimmune disease treatment. The doctor's instructions should be followed carefully. They may differ from the general information in this leaflet.
Cyclaid should not be taken and the doctor should be toldif such a situation applies to the patient. In case of doubts, the doctor should be consulted before taking Cyclaid.
If any of these situations occur before or during treatment with Cyclaid, the doctor should be told immediately.
Cyclaid suppresses the immune system, which increases the risk of developing malignant tumors, especially skin and lymphatic system tumors. Sun exposure and UV radiation should be limited by:
The doctor will monitor the following parameters:
If there are any questions about the action of Cyclaid or the reasons why it has been prescribed to the patient, the doctor should be consulted.
(intermediate or posterior uveitis and Behçet's disease, atopic dermatitis, severe rheumatoid arthritis, or nephrotic syndrome), should not take Cyclaid if:
In patients treated for Behçet's disease, the doctor will closely monitor the patient's condition if they experience neurological symptoms (e.g., increased forgetfulness, personality changes during treatment, psychiatric disorders, or mood disorders, burning sensation in the limbs, decreased sensation in the limbs, tingling in the limbs, weakness in the limbs, gait disturbances, headache with nausea and vomiting or without, vision disturbances, including limited eye movement). The doctor will closely monitor treatment in elderly patients and in patients treated for psoriasis or atopic dermatitis. If Cyclaid has been prescribed to the patient for the treatment of psoriasis or atopic dermatitis, the patient should not be exposed to UVB radiation or undergo phototherapy during treatment.
Cyclaid should not be given to children for the treatment of post-transplant diseases, except for the treatment of nephrotic syndrome.
Experience with the use of Cyclaid in elderly patients is limited. In these patients, the doctor should monitor kidney function. Patients over 65 years of age with psoriasis or atopic dermatitis should be treated with Cyclaid only if their disease is particularly severe.
The doctor or pharmacist should be told about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take. In particular, the doctor or pharmacist should be told if the patient is taking any of the following medicines before or during treatment with Cyclaid:
Cyclaid should not be taken with grapefruit or grapefruit juice, as they may affect the action of Cyclaid.
Before taking any medicine, the doctor or pharmacist should be consulted. The doctor will discuss the risks associated with taking Cyclaid during pregnancy with the patient.
Experience with the use of Cyclaid during pregnancy is limited. Generally, Cyclaid should not be taken during pregnancy. If it is necessary to take this medicine, the doctor will discuss the benefits and risks of taking it during pregnancy with the patient. The doctor should be told if the patient is breastfeeding.Breastfeeding is not recommended during treatment with Cyclaid, as cyclosporin, the active substance of Cyclaid, passes into breast milk. This may affect the breastfed child.
The doctor should be informed if the patient has hepatitis C. Liver function may change during hepatitis C treatment, which may affect cyclosporin blood levels. Close monitoring of cyclosporin blood levels by the doctor and dose adjustment after starting hepatitis C treatment may be necessary.
Cyclaid contains alcohol, which may impair the ability to drive and use machines. Cyclaid contains macrogolglycerol hydroxystearate, which may cause stomach upset and diarrhea.
This medicine contains 25 mg, 50 mg, 100 mg of alcohol (ethanol) in each capsule containing 25 mg, 50 mg, 100 mg of cyclosporin, respectively. A dose of 500 mg of cyclosporin contains 500 mg of ethanol, which is equivalent to less than 13 ml of beer or 5 ml of wine. The small amount of alcohol in this medicine will not have noticeable effects.
The medicine contains 47.25 mg of propylene glycol in each 25 mg capsule. The medicine contains 79 mg of propylene glycol in each 50 mg capsule. The medicine contains 136.5 mg of propylene glycol in each 100 mg capsule. Before administering the medicine to a child under 4 weeks of age, the doctor or pharmacist should be consulted, especially if the child is taking other medicines containing propylene glycol or alcohol.
This medicine should always be taken as directed by the doctor. In case of doubts, the doctor should be consulted. The patient should not take more of the medicine than recommended. The doctor will adjust the dose of this medicine according to the patient's health condition. Too much medicine may affect kidney function. The patient will have regular blood tests and hospital visits, especially after transplantation. The patient will be able to discuss treatment and any problems with the doctor.
The doctor will adjust the dose of Cyclaid for the patient. The dose depends on the patient's body weight and the reason for taking the medicine. The doctor will also inform the patient how often to take the medicine.
After changing treatment from one oral form of cyclosporin to another: The doctor will closely monitor the patient's condition for a short time. The patient may experience certain side effects. If this happens, the doctor or pharmacist should be told. A dose change may be necessary. The dose should never be changed without the doctor's advice.
Cyclaid should be taken every day at the same time. This is very important in transplant patients.
The daily dose should always be taken in two divided doses. The capsules should be removed from the blister pack. The capsules should be swallowed whole, with a glass of water.
The doctor will inform the patient how long to take Cyclaid. This depends on whether the patient is taking the medicine after receiving a transplant or for the treatment of severe skin diseases, rheumatoid arthritis, uveitis, or nephrotic syndrome. In the case of severe flare-ups, treatment usually lasts 8 weeks. Cyclaid should be continued for as long as the doctor recommends. If there are any questions about how long to take Cyclaid, the doctor or pharmacist should be consulted.
If more than the recommended dose of the medicine is taken by accident, the doctor or the emergency department of the nearest hospital should be notified immediately. The patient may need medical attention.
If the patient forgets to take a dose of the medicine, it should be taken as soon as possible. If it is almost time for the next dose, the missed dose should be skipped. The medicine should then be taken as before. A double dose should not be taken to make up for a missed dose.
Treatment with Cyclaid should not be stopped unless the doctor recommends it. Cyclaid should be continued even if the patient feels well. Stopping treatment with Cyclaid may increase the risk of rejecting the transplanted organ. If there are any further doubts about taking this medicine, the doctor or pharmacist should be consulted.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The doctor should be told immediatelyif the patient notices any of the following serious side effects:
Like other medicines that affect the immune system, cyclosporin may change the body's ability to fight infections and may cause the development of tumors or other malignant diseases, especially skin and lymphatic system tumors. Signs of infection may include fever or sore throat.
Changes in vision, loss of coordination, clumsiness, memory loss, difficulty speaking or understanding what others say, and muscle weakness. These may be symptoms of a brain infection called progressive multifocal leukoencephalopathy.
Brain disorders with symptoms such as seizures, confusion, disorientation, decreased responsiveness, personality changes, agitation, insomnia, changes in vision, blindness, coma, paralysis of part or all of the body, stiffness of the neck, loss of coordination with (or without) speech or eye movement disorders.
Swelling of the back of the eye. This may be related to blurred vision. It may also affect vision due to increased pressure in the head (non-tumor-related intracranial hypertension).
Liver disorders with yellowing of the eyes or skin, or without these symptoms, nausea, loss of appetite, dark urine.
Kidney disorders that can significantly reduce the amount of urine produced.
A low number of red blood cells or platelets. Symptoms include pale skin, feeling tired, shortness of breath, dark urine (a sign of red blood cell breakdown), bruising or bleeding without an apparent cause, feeling confused or disoriented, decreased sensitivity, and kidney disorders.
Very common side effects:may affect more than 1 in 10 people.
Kidney function disorders.
High blood pressure.
Headache.
Uncontrolled trembling of the body.
Excessive hair growth on the body and face.
High blood lipid levels.
If any of these symptoms occur, the doctor should be told.
Common side effects:may affect 1 to 10 people in 100.
Seizures (convulsions).
Liver function disorders.
High blood sugar levels.
Fatigue.
Lack of appetite.
Nausea, vomiting, abdominal pain, constipation, diarrhea.
Excessive hair growth.
Acne, sudden flushing.
Fever.
Low white blood cell count.
Numbness or tingling.
Muscle pain, muscle cramps.
Stomach ulcers.
Gum overgrowth covering the teeth.
High levels of uric acid and potassium in the blood, low magnesium levels in the blood.
If any of these symptoms occur, the doctor should be told.
Uncommon side effects:may affect 1 to 10 people in 1,000.
Brain disorders with symptoms such as sudden seizures, confusion, disorientation, insomnia, agitation, changes in vision, loss of consciousness, feeling weak, movement disorders.
Rash.
General swelling.
Weight gain.
Low red blood cell or platelet count, which may increase the risk of bleeding.
If any of these symptoms occur, the doctor should be told.
Rare side effects:may affect 1 to 10 people in 10,000.
Nerve disorders with numbness or tingling in the fingers and toes.
Pancreatitis with severe abdominal pain.
Muscle weakness, loss of muscle strength, muscle pain in the legs or arms or other muscles of the body.
Red blood cell destruction, including kidney disorders with symptoms such as swelling of the face, abdomen, hands, and/or feet, decreased urine production, breathing difficulties, chest pain, seizures, loss of consciousness.
Changes in the menstrual cycle, breast enlargement in men.
If any of these symptoms occur, the doctor should be told.
Very rare side effects:may affect 1 to 10 people in 100,000.
Swelling of the back of the eye, which may be related to increased pressure in the head and vision disturbances.
If any of these symptoms occur, the doctor should be told.
Other side effects with unknown frequency:frequency cannot be estimated from the available data.
Severe liver disorders with yellowing of the eyes or skin, or without these symptoms, nausea, loss of appetite, dark urine, swelling of the face, hands, feet, and/or whole body.
Bleeding under the skin or purple spots on the skin, sudden bleeding without an apparent cause.
Migraine or severe headache, often with nausea or vomiting and sensitivity to light.
Pain in the legs and feet.
Hearing loss.
If any of these symptoms occur, the doctor should be told.
No additional side effects are expected in children and adolescents compared to adults.
If side effects occur, including any side effects not listed in the leaflet, the doctor or pharmacist should be told. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children. This medicine does not require special storage temperature conditions. It should be stored in the original packaging to protect it from light and moisture. The capsules should be stored in blister packs. The packaging should be removed just before taking the medicine. The medicine should not be taken after the expiry date stated on the blister pack and carton after "EXP". The expiry date refers to the last day of the month stated. After opening the blister pack, a characteristic smell of the medicine can be noticed. This is normal and does not mean that the capsules are not suitable for use. Medicines should not be disposed of via wastewater or household waste. The pharmacist should be asked how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of Cyclaid is cyclosporin. Each soft capsule contains 25 mg, 50 mg, or 100 mg of cyclosporin. The other ingredients are: Capsule contents: anhydrous ethanol, all-rac-α-tocopheryl acetate (E 307), ethylene glycol monoethyl ether, macrogolglycerol oleate, macrogolglycerol hydroxystearate. Capsule shell: gelatin, glycerol, propylene glycol, titanium dioxide (E171), iron oxide black (E172) (only 25 mg and 100 mg).
Cyclaid is available in three strengths: 25 mg: soft capsule, gray in color. 50 mg: soft capsule, white in color. 100 mg: soft capsule, gray in color. The packaging contains 50 or 60 soft capsules in aluminum/aluminum blister packs. Not all pack sizes may be marketed.
ul. Sokratesa 13D lok. 27
01-909 Warsaw
Poland
Morningside Pharmaceuticals Ltd.
5 Pavilion Way, Castle Business Park
Loughborough
Leicestershire, LE11 5GW
United Kingdom
Monteresearch s.r.l
Via IV Novembre n.92
Medis International a.s., production plant Bolatice
Průmyslová 961/16
747 23 Bolatice
Czech Republic
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.